Skip to main content
Journal of Experimental Orthopaedics

Table 2 Baseline characteristics of RA

From: Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

Baseline characteristic

Naïve group (n = 25)

Switch group (n = 11)

P

Disease duration (years)

13.2 ± 2.0

15.5 ± 2.7

n.s

Steinbrocker

 Stage (I/II/III/IV)

1/2/4/18

0/2/1/7

n.s

 Class (1/2/3/4)

2/8/15/0

0/3/8/0

n.s

 RF positive (%)

68.0

72.7

n.s

 ACPA positive (%)

72.0

81.8

n.s

 DAS28-ESR

3.60 ± 0.17

4.15 ± 0.32

n.s

 SDAI

6.90 ± 1.00

9.93 ± 1.38

n.s

 MTX (%)

60.0

45.5

n.s

 MTX dose (mg/week)

8.1 ± 0.9

7.2 ± 1.4

n.s

 PSL (%)

32.0

54.5

n.s

 PSL dose (mg/day)

5.3 ± 1.8

3.2 ± 0.6

n.s

 bDMARDs (%)

32.0

54.5

n.s

 bDMARDs

IFX 2, ADA 1, TCZ 3, GLM 1, ABT 1

ETN 2, TCZ 1, GLM 2, ABT 1

 

 csDMARDs (%)

36.0

27.3

n.s

  1. Data are presented as means ± standard deviation (SD), RA: rheumatoid arthritis; Naïve group: treatment-naïve group; Switch group: transitioning from bisphosphonate group; ACPA: anti-cyclic citrullinated peptide antibody; RF: rheumatoid factor; DAS: disease activity score; SDAI: simplified disease activity score; MTX: methotrexate; PSL: prednisolone; bDMARDs: biological disease-modifying anti-rheumatic drugs; csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs (salazosulfapyridine, iguratimod, bucillamine, tacrolimus); TCZ: tocilizumab; ETN: etanercept; ADA: adalimumab; ABT: abatacept
  2. P values from Mann-Whitney U tests for continuous variables and Chi-squared tests or Fisher’s exact tests for dichotomous variables
Back to article page